CN Patent

CN105085396B — 用于制备贝达喹啉的中间体及其制备方法和应用

Assigned to Shanghai Institute of Pharmaceutical Industry · Expires 2017-08-08 · 9y expired

What this patent protects

本发明公开了一种用于制备贝达喹啉的中间体及其制备方法，本发明的优势在于：避免了中间体中的α位氢和烯醇化，减少了副反应的发生，提高了原料的转化率和反应的总收率，适合大规模工业化生产。用于制备贝达喹啉的中间体，其特征在于，为具有式(9)结构式的化合物或其光学异构体：

USPTO Abstract

本发明公开了一种用于制备贝达喹啉的中间体及其制备方法，本发明的优势在于：避免了中间体中的α位氢和烯醇化，减少了副反应的发生，提高了原料的转化率和反应的总收率，适合大规模工业化生产。用于制备贝达喹啉的中间体，其特征在于，为具有式(9)结构式的化合物或其光学异构体：

Drugs covered by this patent

Patent Metadata

Patent number
CN105085396B
Jurisdiction
CN
Classification
—
Expires
2017-08-08
Drug substance claim
No
Drug product claim
No
Assignee
Shanghai Institute of Pharmaceutical Industry
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.